Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).
- DOI
- 10.1016/j.ahj.2025.02.011
- Published
- 2025 Jul
- Container
- American heart journal
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ahj.2025.02.011,
title = {Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).},
author = {Gibson CM and Bahit MC and Mehran R and Mehta SR and Lamee RA and Goto S and Weitz JI and Horrow J and Barnathan ES and Harrington RA and Mahaffey KW and Lam CSP and Pieper KS and Johnston SC and Hankey GJ and Plotnikov AN and Li D and Deng H and Steg PG and Librexia ACS Committees and Investigators.},
year = {2025},
journal = {American heart journal},
doi = {10.1016/j.ahj.2025.02.011},
url = {https://doi.org/10.1016/j.ahj.2025.02.011}
}RIS
TY - JOUR TI - Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). AU - Gibson CM AU - Bahit MC AU - Mehran R AU - Mehta SR AU - Lamee RA AU - Goto S AU - Weitz JI AU - Horrow J AU - Barnathan ES AU - Harrington RA AU - Mahaffey KW AU - Lam CSP AU - Pieper KS AU - Johnston SC AU - Hankey GJ AU - Plotnikov AN AU - Li D AU - Deng H AU - Steg PG AU - Librexia ACS Committees and Investigators. PY - 2025 JO - American heart journal DO - 10.1016/j.ahj.2025.02.011 UR - https://doi.org/10.1016/j.ahj.2025.02.011 ER -
APA
CM, G., MC, B., R, M., SR, M., RA, L., S, G., JI, W., J, H., ES, B., RA, H., KW, M., CSP, L., KS, P., SC, J., GJ, H., AN, P., D, L., H, D., PG, S., & Investigators., L. A. C. A. (2025). Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).. American heart journal. https://doi.org/10.1016/j.ahj.2025.02.011
Source records
- pubmed · retrieved 2026-09-26T12:56:36.132Z